GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
Public ClinicalTrials.gov record NCT01049776. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of GW786034 in Patients With Non Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens. An Institutional Pilot Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Lung Cancer is the most common cause of cancer death in the United States with an estimated mortality in excess of 160,000, more than the combined mortality seen with prostate, breast, colorectal cancers(1). Most patients with Lung Cancer have Non-Small Cell Lung Cancers( NSCLC) and only 25-30% of patients with NSCLC (Non Small Cell Lung Cancer) have resectable disease( Stage I or II) at the time of diagnosis. The vast majority of patients with advanced NSCLC (Non Small Cell Lung Cancer) are not curable and overall five year survival is 11%-14%1. Chemotherapy is beneficial for patients with locally advanced and metastatic disease. Numerous phase III studies have determined the superiority of systemic chemotherapy over best supportive care. Platinum based chemotherapy has been widely accepted as the standard of care for the initial treatment of advanced NSCLC. However first line chemotherapy is modest at best. A randomized trial comparing four of the most commonly used chemotherapy regimens in the United States not only failed to show a clearly superior arm but also confirmed the dismal prognosis of these patients. The response rate for all 1207 patients was 18.6% with a median survival of eight months and one year survival of 33.5 % and a two year survival of 12%5. Clearly a different paradigm is needed for the treatment of this disease.
Study identification
- NCT ID
- NCT01049776
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2009
- Primary completion
- Feb 28, 2014
- Completion
- Not listed
- Last update posted
- Sep 18, 2014
Started 2010
United States locations
- U.S. sites
- 13
- U.S. states
- 1
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Illinois CancerCare, P.C. | Bloomington | Illinois | 61701 | — |
| Illinois CancerCare, P.C. | Canton | Illinois | 61520 | — |
| Illinois CancerCare, P.C. | Carthage | Illinois | 62321 | — |
| Illinois CancerCare, P.C. | Eureka | Illinois | 61530 | — |
| Illinois CancerCare, P.C. | Galesburg | Illinois | 61401 | — |
| Illinois CancerCare, P.C. | Macomb | Illinois | 61455 | — |
| Illinois CancerCare, P.C. | Monmouth | Illinois | 61462 | — |
| Illinois CancerCare, P.C. | Normal | Illinois | 61761 | — |
| Illinois CancerCare, P.C. | Ottawa | Illinois | 61350 | — |
| Illinois CancerCare, P.C. | Pekin | Illinois | 61554 | — |
| Illinois CancerCare, P.C. | Peoria | Illinois | 61615 | — |
| Illinois CancerCare, P.C. | Peru | Illinois | 61354 | — |
| Illinois CancerCare, P.C. | Princeton | Illinois | 61356 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01049776, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2014 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01049776 live on ClinicalTrials.gov.